478 related articles for article (PubMed ID: 24877765)
1. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.
Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D
Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
3. Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).
Schmidt ST; Pedersen GK; Neustrup MA; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Front Immunol; 2018; 9():898. PubMed ID: 29760705
[TBL] [Abstract][Full Text] [Related]
4. The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.
Schmidt ST; Khadke S; Korsholm KS; Perrie Y; Rades T; Andersen P; Foged C; Christensen D
J Control Release; 2016 Oct; 239():107-17. PubMed ID: 27574990
[TBL] [Abstract][Full Text] [Related]
5. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
[TBL] [Abstract][Full Text] [Related]
7. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.
Liu C; Chu X; Sun P; Feng X; Huang W; Liu H; Ma Y
Hum Vaccin Immunother; 2018 Apr; 14(4):931-940. PubMed ID: 29271696
[TBL] [Abstract][Full Text] [Related]
8. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.
Hansen J; Lindenstrøm T; Lindberg-Levin J; Aagaard C; Andersen P; Agger EM
Cancer Immunol Immunother; 2012 Jun; 61(6):893-903. PubMed ID: 22095092
[TBL] [Abstract][Full Text] [Related]
9. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
10. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
[TBL] [Abstract][Full Text] [Related]
11. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
[TBL] [Abstract][Full Text] [Related]
12. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
14. Method of manufacturing CAF®09 liposomes affects immune responses induced by adjuvanted subunit proteins.
Thakur A; Wadhwa A; Lokras A; Müllertz OAO; Christensen D; Franzyk H; Foged C
Eur J Pharm Biopharm; 2023 Aug; 189():84-97. PubMed ID: 37059402
[TBL] [Abstract][Full Text] [Related]
15. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
17. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity.
Song YC; Cheng HY; Leng CH; Chiang SK; Lin CW; Chong P; Huang MH; Liu SJ
J Control Release; 2014 Jan; 173():158-65. PubMed ID: 24177312
[TBL] [Abstract][Full Text] [Related]
18. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves.
Thakur A; Andrea A; Mikkelsen H; Woodworth JS; Andersen P; Jungersen G; Aagaard C
PLoS One; 2018; 13(7):e0201253. PubMed ID: 30063728
[TBL] [Abstract][Full Text] [Related]
20. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
Jackson RJ; Worley M; Trivedi S; Ranasinghe C
Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
